ArticleFrontiers in neuroscience2025
A lightweight triple-modal fusion network for progressive mild cognitive impairment prediction in Alzheimer's disease.
Article in Frontiers in neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: As a progressive neurodegeneration, Alzheimer's disease (AD) represents the primary etiology of dementia among the elderly. Early identification of individuals with mild cognitive impairment (MCI) who are likely to convert to AD is essential for timely diagnosis and therapeutic intervention. Although multimodal neuroimaging and clinical data provide complementary information, existing fusion models often face challenges such as high computational complexity and limited interpretability. Methods: To address these limitations, we introduce TriLightNet, an innovative lightweight triple-modal fusion network designed to integrate structural MRI, functional PET, and clinical tabular data for predicting MCI-to-AD conversion. TriLightNet incorporates a hybrid backbone that combines Kolmogorov-Arnold Networks with PoolFormer for efficient feature extraction. Additionally, it introduces a Hybrid Block Attention Module to capture subtle interactions between image and clinical features and employs a MultiModal Cascaded Attention mechanism to enable progressive and efficient fusion across the modalities. These components work together to streamline multimodal data integration while preserving meaningful insights. Results: Extensive experiments conducted on the Alzheimer's Disease Neuroimaging Initiative (ADNI) dataset demonstrate the effectiveness of TriLightNet, showcasing superior performance compared to state-of-the-art methods. Specifically, the model achieves an accuracy of 81.25%, an AUROC of 0.8146, and an F1-score of 69.39%, all while maintaining reduced computational costs. Discussion: Furthermore, its interpretability was validated using the Integrated Gradients method, which revealed clinically relevant brain regions contributing to the predictions, enhancing its potential for meaningful clinical application. Our code is available at https://github.com/sunyzhi55/TriLightNet.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.